LOGIN  |  REGISTER
Cue Biopharma

Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners

March 14, 2022 | Last Trade: US$1.94 0.26 -11.82

Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical abdominal adhesions. The live virtual event will begin Wednesday March 16th 2022 at 8:30 am ET and be available by replay. >> Click here to register or attend.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Palisade Bio to present clinical data on LB1148 on prevention of post-surgical abdominal adhesions.
  • Ronald Hurst, MD, Principal Investigator of the study and Michael Dawson, MD, to participate in virtual presentation to review data and the need for new options to
  • The webinar will be hosted by Stonegate Capital Partners on March 16th at 8:30 am ET.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/116651_figure1_550.jpg

 About Stonegate Capital Partners

Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.

Contacts:

Erol Girgin
214.987.4121
This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: Stonegate, Inc.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page